BR112017004140B1 - Agente de imagemamento, seu uso e compostos - Google Patents

Agente de imagemamento, seu uso e compostos Download PDF

Info

Publication number
BR112017004140B1
BR112017004140B1 BR112017004140-5A BR112017004140A BR112017004140B1 BR 112017004140 B1 BR112017004140 B1 BR 112017004140B1 BR 112017004140 A BR112017004140 A BR 112017004140A BR 112017004140 B1 BR112017004140 B1 BR 112017004140B1
Authority
BR
Brazil
Prior art keywords
imidazo
pyridine
carbonitrile
methoxy
methylamino
Prior art date
Application number
BR112017004140-5A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112017004140A2 (pt
Inventor
Celia Dominguez
John Wityak
Jonathan Bard
Alex Kiselyov
John Christopher Brown
Michael Edward Prime
Peter David Johnson
Daniel Clarke-Frew
Original Assignee
Chdi Foundation, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chdi Foundation, Inc. filed Critical Chdi Foundation, Inc.
Publication of BR112017004140A2 publication Critical patent/BR112017004140A2/pt
Publication of BR112017004140B1 publication Critical patent/BR112017004140B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0497Organic compounds conjugates with a carrier being an organic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR112017004140-5A 2014-08-29 2015-08-28 Agente de imagemamento, seu uso e compostos BR112017004140B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462043590P 2014-08-29 2014-08-29
US62/043,590 2014-08-29
PCT/US2015/047401 WO2016033440A1 (en) 2014-08-29 2015-08-28 Probes for imaging huntingtin protein

Publications (2)

Publication Number Publication Date
BR112017004140A2 BR112017004140A2 (pt) 2017-12-12
BR112017004140B1 true BR112017004140B1 (pt) 2023-01-10

Family

ID=55400645

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017004140-5A BR112017004140B1 (pt) 2014-08-29 2015-08-28 Agente de imagemamento, seu uso e compostos

Country Status (20)

Country Link
US (2) US11104691B2 (https=)
EP (1) EP3197277B1 (https=)
JP (1) JP6754353B2 (https=)
KR (1) KR102410733B1 (https=)
CN (1) CN107105667B (https=)
AU (2) AU2015308769A1 (https=)
BR (1) BR112017004140B1 (https=)
CA (1) CA2959533C (https=)
DK (1) DK3197277T3 (https=)
EA (1) EA039923B1 (https=)
ES (1) ES2905095T3 (https=)
HR (1) HRP20220001T1 (https=)
HU (1) HUE057702T2 (https=)
IL (1) IL250802B (https=)
MX (1) MX386798B (https=)
PL (1) PL3197277T3 (https=)
PT (1) PT3197277T (https=)
SG (1) SG11201701592SA (https=)
SI (1) SI3197277T1 (https=)
WO (1) WO2016033440A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE056957T2 (hu) 2014-08-29 2022-04-28 Chdi Foundation Inc Próbák huntingtin fehérjét megjelenítõ képalkotásra
AU2015308709B2 (en) 2014-08-29 2020-01-02 Chdi Foundation, Inc. Probes for imaging huntingtin protein
DK3197277T3 (da) 2014-08-29 2022-01-31 Chdi Foundation Inc Prober til billeddannelse af huntingtin-protein
EP3186241B1 (en) 2014-08-29 2020-10-07 CHDI Foundation, Inc. Probes for imaging huntington protein
PT3340796T (pt) 2015-08-28 2021-07-28 Chdi Foundation Inc Sondas para imagens da proteína huntingtina
AU2018346962A1 (en) * 2017-10-12 2020-05-28 BCN Biosciences L.L.C. Methods of treating radiation induced gastrointestinal syndrome
JP7619952B2 (ja) 2019-02-25 2025-01-22 シーエイチディーアイ ファウンデーション,インコーポレーテッド 変異型ハンチンチンタンパク質を標的とするための化合物及びその使用
WO2020227576A1 (en) 2019-05-09 2020-11-12 Genentech, Inc. Regio-selective synthesis of imidazo[1,2-a]pyrimidines
CN114773312B (zh) * 2021-10-29 2024-03-26 北京鑫诺康桥药物研究有限公司 一种盐酸阿罗洛尔中间体的制备工艺

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10050663A1 (de) * 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
EP1655287A1 (en) * 2003-08-13 2006-05-10 BF Research Institute, Inc. Probe for diseases with amyloid accumulation, amyloid-staining agent, remedy and preventive for diseases with amyloid accumulation and diagnostic probe and staining agent for neurofibrillary change
CN101501033B (zh) * 2006-06-21 2012-08-01 通用电气医疗有限公司 对淀粉状蛋白具有亲和性的化合物
WO2008016648A2 (en) * 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
KR20090091287A (ko) * 2006-11-17 2009-08-27 니혼 메디피직스 가부시키가이샤 신규 아밀로이드 친화성 화합물
EP2098522B1 (en) * 2006-11-30 2011-10-19 Nihon Medi-Physics Co., Ltd. Compounds having affinity for amyloid
EP2125800A1 (en) 2007-01-22 2009-12-02 AstraZeneca AB Novel heteroaryl substituted imidazo ý1,2 -a¨pyridine derivatives
CN101909658A (zh) * 2007-10-30 2010-12-08 日本医事物理股份有限公司 对淀粉样蛋白具有亲和性的新化合物的应用及制备方法
FR2928923B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques
CA2731738A1 (en) * 2008-07-24 2010-01-28 Siemens Medical Solutions Usa, Inc. Imaging agents useful for identifying ad pathology
CN102224423B (zh) * 2008-09-23 2014-10-22 维斯塔实验室有限公司 聚集的τ分子的配体
WO2010141805A1 (en) * 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heterocyclic amides as modulators of trpa1
CA2836872A1 (en) * 2011-05-20 2012-11-29 Nihon Medi-Physics Co., Ltd. Novel compound having affinity for amyloid
JP5167436B2 (ja) * 2011-06-24 2013-03-21 日本メジフィジックス株式会社 新規アミロイド親和性化合物
JP2013237655A (ja) 2012-05-17 2013-11-28 Kyoto Univ コンフォメーション病診断用分子プローブ
WO2014076021A1 (en) * 2012-11-14 2014-05-22 F. Hoffmann-La Roche Ag Imidazopyridine derivatives
SI2970255T1 (sl) 2013-03-14 2017-12-29 Galapagos Nv Spojine in farmacevtski sestavki le-teh za zdravljenje vnetnih motenj
JP6182668B2 (ja) * 2013-09-26 2017-08-16 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 画像化ツールとしてのイミダゾ[1,2−a]ピリジン−7−アミン
DK3197277T3 (da) 2014-08-29 2022-01-31 Chdi Foundation Inc Prober til billeddannelse af huntingtin-protein
EP3186241B1 (en) 2014-08-29 2020-10-07 CHDI Foundation, Inc. Probes for imaging huntington protein
AU2015308709B2 (en) 2014-08-29 2020-01-02 Chdi Foundation, Inc. Probes for imaging huntingtin protein
HUE056957T2 (hu) 2014-08-29 2022-04-28 Chdi Foundation Inc Próbák huntingtin fehérjét megjelenítõ képalkotásra
PT3340796T (pt) 2015-08-28 2021-07-28 Chdi Foundation Inc Sondas para imagens da proteína huntingtina

Also Published As

Publication number Publication date
CA2959533C (en) 2023-03-07
EA201790400A1 (ru) 2017-09-29
CA2959533A1 (en) 2016-03-03
AU2015308769A1 (en) 2017-03-23
IL250802A0 (en) 2017-04-30
EP3197277B1 (en) 2021-12-22
JP6754353B2 (ja) 2020-09-09
EP3197277A4 (en) 2018-04-18
EA039923B1 (ru) 2022-03-28
IL250802B (en) 2020-08-31
AU2019283999B2 (en) 2021-07-22
US20210380608A1 (en) 2021-12-09
US11104691B2 (en) 2021-08-31
ES2905095T3 (es) 2022-04-07
JP2017529340A (ja) 2017-10-05
PL3197277T3 (pl) 2022-04-04
PT3197277T (pt) 2022-02-01
WO2016033440A1 (en) 2016-03-03
BR112017004140A2 (pt) 2017-12-12
US11851446B2 (en) 2023-12-26
EP3197277A1 (en) 2017-08-02
HRP20220001T1 (hr) 2022-04-01
DK3197277T3 (da) 2022-01-31
CN107105667A (zh) 2017-08-29
SG11201701592SA (en) 2017-03-30
KR20170047303A (ko) 2017-05-04
SI3197277T1 (sl) 2022-04-29
MX2017002702A (es) 2017-10-23
US20170283439A1 (en) 2017-10-05
HUE057702T2 (hu) 2022-05-28
CN107105667B (zh) 2021-08-17
AU2019283999A1 (en) 2020-01-23
MX386798B (es) 2025-03-19
KR102410733B1 (ko) 2022-06-20

Similar Documents

Publication Publication Date Title
US11851446B2 (en) Probes for imaging Huntingtin protein
US12036291B2 (en) Probes for imaging huntingtin protein
BR112017004141B1 (pt) Agente de imagemamento e seu uso
ES2818107T3 (es) Sondas para obtener imágenes de la proteína huntingtina
CA2995847C (en) Probes for imaging huntingtin protein
HK1241224B (en) Probes for imaging huntingtin protein
HK1240582A1 (en) Probes for imaging huntington protein
HK1240582B (en) Probes for imaging huntington protein
HK1241223B (en) Probes for imaging huntingtin protein
HK1241223A1 (en) Probes for imaging huntingtin protein

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 11.1 NA RPI NO 2493 DE 16/10/2018 POR TER SIDO INDEVIDA.

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B15V Prolongation of time limit allowed

Free format text: DE ACORDO COM COMUNICADO PUBLICADO NA RPI 2487 DE 04/09/2018, COMUNICADO PUBLICADO NA RPI 2488 DE 11/09/2018 E RESOLUCAO INPI/PR NO 225/2018 FICAM DEVOLVIDOS ATE 14/09/2019 OS PRAZOS VENCIDOS NAS DATAS DIVULGADOS DENTRO DOS COMUNICADOS.

B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 11.1 NA RPI NO 2495 DE 30/10/2018 POR TER SIDO INDEVIDA.

B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: A01N 57/00

Ipc: C07D 471/04 (2006.01), A61K 51/04 (2006.01)

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/08/2015, OBSERVADAS AS CONDICOES LEGAIS